STR-V003
/ Starna Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 27, 2025
Highly Effective mRNA-LNP Vaccine Against Respiratory Syncytial Virus (RSV) in Multiple Models.
(PubMed, Vaccines (Basel))
- "STR-V003 demonstrates a favorable safety profile and induces robust protective immunity against RSV."
Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
April 03, 2024
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Starna Therapeutics
New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 2
Of
2
Go to page
1